The cardioprotective effects of PTEN inhibition during chronic AngII exposure suggest it could potentially serve as an adjunct therapy in conditions requiring clinical AngII administration or in patients with hypertension-induced cardiac remodeling. The gene discussed is AGT; the disease is hypertensive disorder.